About Us

Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.

As cancer cells evolve, they acquire genetic vulnerabilities that normal cells do not have. These vulnerabilities offer a unique pathway for precisely targeting treatments.

These genetic vulnerabilities are readily measurable and can often act as biomarkers, allowing the identification of patients who may derive the most benefit from targeted therapies.

Biomarker-driven approaches are mitigating some of the clinical development risks inherent in drug development. They are also evolving cancer care for both hematologic malignancies and solid tumors by accelerating delivery of new therapies that provide clinical benefit to patients, with potentially fewer side effects.

Additionally, Calithera is advancing an investigational, selective oral inhibitor of arginase (CB-280) for the treatment of cystic fibrosis, a first-in-class approach for combating the disease for which there is great need for new treatment approaches.

Meet Our Team

We are dedicated to targeting cancer differently.

Meet the Team